SINCO PHARMA (06833) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 1.032 billion, a decrease of 13.66% year-on-year. Profit attributable to shareholders of the company stood at RMB 19.909 million, reflecting a decline of 18.37% compared to the same period last year, with earnings per share at RMB 0.0098.

In line with the reduction in group revenue, the gross profit for the reporting period decreased by RMB 6.6 million to RMB 124 million, compared to RMB 130.7 million for the six months ended June 30, 2025. Despite this, the gross profit margin improved from 10.9% to 12.0%, driven by lower procurement costs and a stronger Renminbi against the US dollar, which reduced the cost of sales.

These figures highlight the company's ongoing operational adjustments amid challenging market conditions, while the margin expansion signals improved cost efficiency despite the top-line contraction.